ORGANIC COMPOUNDS

1 . A compound of Formula (I):

R 1 —W—P-Q-R 2   (I)

wherein P is

Q is

W is —N(R 8 )C(O)—, —C(O)N(R 8 )— or a direct bond;

n is 1, 2, or 3;

p is 0, 1, 2, to 2n;

q is 0, 1, 2, or 3;

R 1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, haloalkyl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

R 2 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, haloalkyl, aralkyl, aralkyloxy, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl;

R 3 is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, halo, haloalkyl, trifluoromethoxyl, cyano, hydroxy, or —N(R 8 ) 2 ;

R 5 and R 5a are independently selected from hydrogen, alkyl, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, cycloalkylalkyl or aralkyl;

or R 5 and R 5a are together to form an oxo (═O) group, or to form a cycloaklyl;

R 6 is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, haloalkyl, alkoxy, cycloalkylalkyl, or aralkyl;

or R 5 and R 6 on adjacent carbons are together to form a cycloaklyl, or to form an aryl;

R 7 is hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, cycloalkylalkyl or aralkyl; and

R 8 is hydrogen, alkyl, hydroxyalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl or aralkyl;

a pharmaceutically acceptable salt thereof.

2 . The compound according to claim 1 , wherein P is

3 . The compound according to claim 1 , wherein W is —N(R 8 )C(O)—, and R 1 is hydrogen, alkyl, aryl, aralkyl or heteroarylalkyl.

4 . The compound according to claim 1 , wherein W is a direct bond and R 1 is aryl or heteroaryl.

5 . The compound according to claim 1 , wherein R 2 is hydroxy, C 1 -C 4 alkyl, cycloalkylalkyl, haloalkyl, aralkyl, aralkyloxy or heteroarylalkyl.

6 . The compound according to claim 1 , wherein Q is

7 . The compound according to claim 1 , wherein

P is

Q is

W is —N(R 8 )C(O)—;

R 1 is hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

R 2 is hydroxy, C 1 -C 4 alkyl, cycloalkylalkyl, aryl, aralkyl, aralkyloxy, heteroaryl or heteroarylalkyl; and

R 8 is hydrogen or C 1 -C 4 alkyl.

8 . The compound according to claim 1 , wherein

R 2 is hydroxy, C 1 -C 4 alkyl, cycloalkylalkyl, aralkyl, aralkyloxy or heteroarylalkyl, wherein the cycloalkylalkyl is

aralkyl is

C 1 -C 4 alkyl is

aralkyloxy is

and

heteroarylalkyl is

9 . The compound according claim 1 , wherein

R 2 is C 1 -C 4 alkyl, cycloalkylalkyl, or aralkyl,

wherein the cycloalkylalkyl is

aralkyl is

C 1 -C 4 alkyl is

and heteroarylalkyl is

10 . The compound according to claim 4 , wherein

W is a direct bond and

R 1 is

11 . The compound according to claim 1 , wherein the compound is

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-methylisonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(oxazol-4-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(thiazol-5-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methylpyrazin-2-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(thiazol-2-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(oxazol-2-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((1-methyl-1H-imidazol-4-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((1-methyl-1H-pyrazol-3-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((1-methyl-1H-pyrazol-4-yl)methyl)isonicotinamide,

N-((1H-pyrazol-3-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methylisoxazol-3-yl)methyl)isonicotinamide,

N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

(R)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(2-hydroxy-2-phenylethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((2-methylthiazol-4-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(isoxazol-3-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((2-(trifluoromethyl)thiazol-4-yl)methyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((4-methyl-2-phenylthiazol-5-yl)methyl)isonicotinamide,

N-benzyl-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-3-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-4-ylmethyl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide,

N-(4-fluorobenzyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

N-(cyclopropylmethyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-N-(4-fluorobenzyl)isonicotinamide,

N-(2-cyclopropylethyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

N-benzyl-2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-3-ylmethyl)isonicotinamide,

2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide,

2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-4-ylmethyl)isonicotinamide,

2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-N-(3,4-difluorobenzyl)isonicotinamide,

N-benzyl-2-(1-(cyclopropylmethyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)isonicotinamide,

N-(3,4-difluorobenzyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

N-(4-fluorobenzyl)-2-(2-oxo-3-(pyridin-2-ylmethyl)imidazolidin-1-yl)isonicotinamide,

N-(4-fluorobenzyl)-2-(2-oxo-3-(pyridin-4-ylmethyl)imidazolidin-1-yl)isonicotinamide,

N-(3,4-difluorobenzyl)-2-(2-oxo-3-(pyridin-3-ylmethyl)imidazolidin-1-yl)isonicotinamide,

N-(3,4-difluorobenzyl)-2-(2-oxo-3-(pyridin-2-ylmethyl)imidazolidin-1-yl)isonicotinamide,

N-benzyl-2-(2-oxo-3-(pyridin-4-ylmethyl)imidazolidin-1-yl)isonicotinamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(4-fluorobenzyl)isonicotinamide,

2-(3-((4-(difluoromethyl)phenyl)difluoromethyl)-2-oxoimidazolidin-1-yl)-N-(4-fluorobenzyl)isonicotinamide,

2-(3-(2,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(4-fluorobenzyl)isonicotinamide,

N-benzyl-2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)isonicotinamide,

N-benzyl-2-(2-oxo-4-phenylpyridin-1(2H)-yl)isonicotinamide,

2-oxo-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-carboxylic acid benzylamide,

4-benzyloxy-2-oxo-2H-[1,2′]bipyridinyl-4′-carboxylic acid benzylamide,

4-hydroxy-2-oxo-2H-[1,2′]bipyridinyl-4′-carboxylic acid benzylamide,

N-benzyl-2-(3-benzyl-2-oxopiperidin-1-yl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)isonicotinamide,

N-(4-fluorobenzyl)-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)isonicotinamide,

2-(3-(benzo[c][1,2,5]-thiadiazol-5-ylmethyl)-2-oxoimidazolidin-1-yl)-N-benzylisonicotinamide,

N-((1,3,4-oxadiazol-2-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(benzo[c][1,2,5]-oxadiazol-5-ylmethyl)-2-oxoimidazolidin-1-yl)-N-benzylisonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(1-phenylethyl)-isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)-isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-2-ylmethyl)quinoline-4-carboxamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(pyridin-2-ylmethyl)-isonicotinamide,

N-((3-bromoisoxazol-5-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-phenylisoxazol-3-yl)methyl)-isonicotinamide,

N-((2-chlorothiazol-5-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)-isonicotinamide,

N-((5-methylisoxazol-3-yl)methyl)-2-(2-oxo-3-(4-(trifluoromethoxy)-benzyl)imidazolidin-1-yl)isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-N-(thiazol-5-ylmethyl)-isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)-isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)-isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-N-(thiazol-2-ylmethyl)-isonicotinamide,

N-((5-methylisoxazol-3-yl)methyl)-2-(2-oxo-3-(4-(trifluoromethyl)-benzyl)imidazolidin-1-yl)isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(thiazol-2-ylmethyl)-isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(thiazol-5-ylmethyl)-isonicotinamide,

N-((2-chlorothiazol-5-yl)methyl)-2-(2-oxo-3-(4-(trifluoromethyl)-benzyl)imidazolidin-1-yl)isonicotinamide,

2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-(thiazol-2-ylmethyl)-isonicotinamide,

2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-((5-methylisoxazol-3-yl)methyl)-isonicotinamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methylisoxazol-3-yl)methyl)-isonicotinamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(thiazol-5-ylmethyl)-isonicotinamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)-N-(thiazol-2-ylmethyl)-isonicotinamide,

2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-(thiazol-5-ylmethyl)-isonicotinamide,

2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-2-ylmethyl)-isonicotinamide,

2-(1-(3,4-difluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-((5-methylisoxazol-3-yl)methyl)-isonicotinamide,

2-(1-(3,4-difluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-(thiazol-2-ylmethyl)-isonicotinamide,

2-(1-(3,4-difluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-2-ylmethyl)-isonicotinamide,

2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethyl)-benzyl)imidazolidin-1-yl)isonicotinamide,

2-(2-oxo-3-(4-(trifluoromethoxy)-benzyl)imidazolidin-1-yl)isonicotinamide,

N-((2-chlorothiazol-5-yl)methyl)-2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide, and

N-((2-chlorothiazol-5-yl)methyl)-2-(2-oxo-3-(4-(trifluoromethoxy)-benzyl)imidazolidin-1-yl)isonicotinamide.

12 . A pharmaceutical composition, comprising:

the compound of Formula (I) according to claim 1 and

a pharmaceutically acceptable excipient or carrier.

13 . A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, comprising:

administering to the mammal in need thereof a therapeutically effective amount of a compound of Formula (I) or (II) according to any one of claims 1 - 16 and 18 .

14 . The method according to claim 13 , wherein the disease or condition is metabolic syndrome, Syndrome X, diabetes, insulin resistance, hyperinsulinanemia, reperfusion injury, angiplastic restenosis, thrombosis, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders, weight loss, body mass index or leptin related diseases.

15 . The method according to claim 13 , where the disease or condition is a skin disorder.